Pancreatic Cancer
Surgical exploration ‘highly recommended’ after induction chemotherapy for locally advanced pancreatic cancer
BARCELONA, Spain — Four months of induction combination chemotherapy followed by surgical exploration made secondary resection feasible for about one-third of patients with nonresectable locally advanced pancreatic cancer, according to results of the randomized phase 2 NEOLAP trial presented at European Society for Medical Oncology Congress.
Neoadjuvant therapy may alter biliary microbiome in patients with pancreatic cancer
Top stories in endocrinology: FDA fast tracks CKD drug, DPP-IV inhibitors may increase pancreatic cancer risk
Among the top stories in endocrinology last week were the FDA’s decision to fast track the sodium-glucose cotransporter 2 inhibitor dapagliflozin to delay renal failure in patients with or without diabetes who also have with chronic kidney disease and a study that found adults with type 2 diabetes treated with dipeptidyl-peptidase IV inhibitors were more likely to develop pancreatic cancer than those who received other treatment.